Till Kaltofen

13PUBLICATIONS
21CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jan 13, 2026
Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.

Alexander Scheiter, Simon Mellin, Felix Keil

|Jan 25, 2025
Necroptosis-Related Gene Signature Predicts Prognosis in Patients with Advanced Ovarian Cancer.

Mingjun Zheng, Mirjana Kessler, Udo Jeschke

|Sep 07, 2021
Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gyneco-oncological center in Germany.

Till Kaltofen, Friederike Hagemann, Nadia Harbeck

|Aug 27, 2021
Trace Amine-Associated Receptor 1 (TAAR1) Is a Positive Prognosticator for Epithelial Ovarian Cancer.

Tilman L R Vogelsang, Aurelia Vattai, Elisa Schmoeckel

|Aug 07, 2021
Functional Analysis of Non-Genetic Resistance to Platinum in Epithelial Ovarian Cancer Reveals a Role for the MBD3-NuRD Complex in Resistance Development.

Tabea L Bauer, Katrin Collmar, Till Kaltofen

|Aug 07, 2021
Cytoplasmic Localization of RXRα Determines Outcome in Breast Cancer.

Alaleh Zati Zehni, Falk Batz, Vincent Cavaillès

Pageof 3

Frequent Collaborators

9 joint publications

Udo Jeschke

6 joint publications

Fabian Trillsch

4 joint publications

Theresa Vilsmaier

3 joint publications

Bastian Czogalla